Rivoglitazone

Rivoglitazone
Systematic (IUPAC) name
	(RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	185428-18-6
ATC code	None
PubChem	CID 3055168
UNII	3A3N0634Q6
Chemical data
Formula	C20H19N3O4S
Mol. mass	397.448 g/mol
SMILES	eMolecules & PubChem
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.^[1]^[2]

It is being developed by Daiichi Sankyo Co.

[edit] References

^ Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs 8 (4): 338–44. PMID 17458185.
^ Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC (2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes Obes Metab 13 (9): 806-13. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.